LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article: Asthma bronchiale v kontextu vnitřního lékařství.

    Teřl, Milan

    Vnitrni lekarstvi

    Winter 2018  Volume 63, Issue 11, Page(s) 757–769

    Abstract: The article is supposed to give a modern perspective on etiopatogenesis of asthma and its management. There are accentuated new diagnostics and treatment opportunities as well as coincident areas with others internal fields and pragmatic recommendation ... ...

    Title translation Asthma bronchiale in the context of internal medicine.
    Abstract The article is supposed to give a modern perspective on etiopatogenesis of asthma and its management. There are accentuated new diagnostics and treatment opportunities as well as coincident areas with others internal fields and pragmatic recommendation for daily clinical practice.Key words: allergy - asthma heterogeneity - asthma management - eosinophilia - internal medicine - phenotype-specific therapy - stepwise pharmacotherapy.
    MeSH term(s) Asthma ; Humans ; Internal Medicine
    Language Czech
    Publishing date Winter 2018
    Publishing country Czech Republic
    Document type Journal Article ; Review
    ZDB-ID 138213-5
    ISSN 1801-7592 ; 0042-773X
    ISSN (online) 1801-7592
    ISSN 0042-773X
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 327: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 526: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Managing T2-high severe asthma in HIV-infected patients.

    Terl, Milan / Jesenak, Milos

    The journal of allergy and clinical immunology. In practice

    2021  Volume 9, Issue 2, Page(s) 1041–1043

    MeSH term(s) Antibodies, Monoclonal, Humanized ; Asthma/epidemiology ; HIV Infections/complications ; HIV Infections/drug therapy ; Humans
    Chemical Substances Antibodies, Monoclonal, Humanized ; mepolizumab (90Z2UF0E52)
    Language English
    Publishing date 2021-02-08
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 2843237-X
    ISSN 2213-2201 ; 2213-2198
    ISSN (online) 2213-2201
    ISSN 2213-2198
    DOI 10.1016/j.jaip.2020.11.015
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 7086: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Four seasons of Czech asthma study: asthma characteristics and management reality in the Czech Republic.

    Terl, Milan / Pohunek, Petr / Kuhn, Matyas / Bystron, Jaromir

    The Journal of asthma : official journal of the Association for the Care of Asthma

    2019  Volume 57, Issue 8, Page(s) 898–910

    Abstract: Objective: ...

    Abstract Objective:
    MeSH term(s) Administration, Inhalation ; Adrenergic beta-2 Receptor Agonists/administration & dosage ; Adult ; Aged ; Allergy and Immunology/standards ; Allergy and Immunology/statistics & numerical data ; Allergy and Immunology/trends ; Anti-Asthmatic Agents/administration & dosage ; Asthma/diagnosis ; Asthma/drug therapy ; Budesonide/administration & dosage ; Cross-Sectional Studies ; Czech Republic ; Delayed Diagnosis/statistics & numerical data ; Drug Combinations ; Drug Prescriptions/statistics & numerical data ; Drug Therapy, Combination/methods ; Drug Therapy, Combination/statistics & numerical data ; Female ; Formoterol Fumarate ; Glucocorticoids/administration & dosage ; Guideline Adherence/statistics & numerical data ; Guideline Adherence/trends ; Humans ; Male ; Middle Aged ; Practice Guidelines as Topic ; Pulmonary Medicine/standards ; Pulmonary Medicine/statistics & numerical data ; Pulmonary Medicine/trends ; Societies, Medical/standards ; Young Adult
    Chemical Substances Adrenergic beta-2 Receptor Agonists ; Anti-Asthmatic Agents ; Drug Combinations ; Glucocorticoids ; Budesonide (51333-22-3) ; Formoterol Fumarate (W34SHF8J2K)
    Language English
    Publishing date 2019-05-30
    Publishing country England
    Document type Journal Article ; Multicenter Study ; Observational Study ; Research Support, Non-U.S. Gov't
    ZDB-ID 603816-5
    ISSN 1532-4303 ; 0277-0903
    ISSN (online) 1532-4303
    ISSN 0277-0903
    DOI 10.1080/02770903.2019.1619082
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 18: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Effect of individual allergen sensitization on omalizumab treatment outcomes in patients with severe allergic asthma determined using data from the Czech Anti-IgE Registry.

    Vaník, Petr / Novosad, Jakub / Kirchnerová, Olga / Krčmová, Irena / Teřl, Milan

    Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology

    2020  Volume 16, Page(s) 81

    Abstract: Background: Omalizumab is an efficient drug for patients with uncontrolled severe allergic asthma (SAA). However, little is known about the differences in omalizumab treatment outcomes among patients with different types of atopic sensitization. Here, ... ...

    Abstract Background: Omalizumab is an efficient drug for patients with uncontrolled severe allergic asthma (SAA). However, little is known about the differences in omalizumab treatment outcomes among patients with different types of atopic sensitization. Here, we assessed the effect of sensitization to individual allergens or their combinations on the outcomes of anti-IgE therapy in patients with SAA.
    Methods: We performed a post hoc analysis of data of subgroups of patients enrolled in the Czech Anti-IgE Registry (CAR). The patients were evaluated at baseline and 16 weeks and 12 months after omalizumab treatment initiation. We analyzed the dependence of primary treatment outcomes [global evaluation of treatment effectiveness (GETE) after 16 weeks of treatment, a reduction in severe exacerbation rate (ER), and an improvement in the asthma control test (ACT) result during 12 months of treatment] and secondary outcomes [a reduction in systemic corticosteroid (SCS) use, an improvement in lung functions, and a fraction of exhaled nitric oxide] of patients with SAA treated with omalizumab for 12 months on sensitization to different perennial aeroallergens. We assessed sensitization to house dust mites, molds, and pets at baseline using skin prick tests and/or specific IgE measurement (semiquantitative evaluation). We compared polysensitized patients (sensitized to all tested allergens) with monosensitized (single positivity) or partially polysensitized patients (combined positivity but not to all allergens).
    Results: We enrolled 279 patients (58.3% women, mean age 52.9 years). Omalizumab treatment presented an 82.8% response rate (according to GETE). It significantly reduced severe asthma exacerbations and SCS use, and improved the ACT result in 161 responders. We identified a subgroup of responders with distinct sensitization patterns (polysensitization to all tested perennial allergens) with higher odds of being responders (OR = 2.217, p = 0.02) and lower tendency to improve ACT result (OR 0.398, p = 0.023) and reduce ER (OR 0.431, p = 0.034) than non-polysensitized patients.
    Conclusions: The clinical benefit of sensitization for patients with SAA receiving omalizumab may be particularly dependent on sensitization pattern. Polysensitized patients showed a higher tendency to be responders (GETE), but a lower tendency to improve the ACT result and reduce ER than non-polysensitized patients.
    Language English
    Publishing date 2020-09-15
    Publishing country England
    Document type Journal Article
    ZDB-ID 2434973-2
    ISSN 1710-1492 ; 1710-1484
    ISSN (online) 1710-1492
    ISSN 1710-1484
    DOI 10.1186/s13223-020-00479-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6713: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Use of dupilumab in a patient with atopic dermatitis, severe asthma, and HIV infection.

    Brodska, Petra / Panzner, Petr / Sedlacek, Dalibor / Terl, Milan / Cetkovska, Petra

    Dermatologic therapy

    2020  Volume 33, Issue 6, Page(s) e14159

    Abstract: Dupilumab is a monoclonal antibody against interleukin 4 (IL-4) receptor α that blocks signaling from IL-4 and IL-13, essential mediators of T helper 2 (Th2) pathway. To date, all clinical trials investigating the use of dupilumab excluded patients with ... ...

    Abstract Dupilumab is a monoclonal antibody against interleukin 4 (IL-4) receptor α that blocks signaling from IL-4 and IL-13, essential mediators of T helper 2 (Th2) pathway. To date, all clinical trials investigating the use of dupilumab excluded patients with human immunodeficiency virus. Herein, we describe the safe and successful use of dupilumab in a patient with atopic dermatitis, severe therapy resistant asthma, and HIV infection.
    MeSH term(s) Adult ; Antibodies, Monoclonal, Humanized ; Asthma/diagnosis ; Asthma/drug therapy ; Dermatitis, Atopic/diagnosis ; Dermatitis, Atopic/drug therapy ; HIV Infections/complications ; HIV Infections/diagnosis ; HIV Infections/drug therapy ; Humans ; Interleukin-13 ; Male
    Chemical Substances Antibodies, Monoclonal, Humanized ; Interleukin-13 ; dupilumab (420K487FSG)
    Language English
    Publishing date 2020-09-09
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 1354801-3
    ISSN 1529-8019 ; 1396-0296
    ISSN (online) 1529-8019
    ISSN 1396-0296
    DOI 10.1111/dth.14159
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5181: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Real-world effectiveness and safety of omalizumab in patients with uncontrolled severe allergic asthma from the Czech Republic.

    Kirchnerová, Olga Růžičková / Valena, Tomáš / Novosad, Jakub / Teřl, Milan

    Postepy dermatologii i alergologii

    2018  Volume 36, Issue 1, Page(s) 34–43

    Abstract: Introduction: This was a sub-group analysis of patients with uncontrolled persistent allergic asthma (AA) in the healthcare setting of the Czech Republic, from a global non-interventional, 2-year post-marketing, observational eXpeRience registry.: Aim! ...

    Abstract Introduction: This was a sub-group analysis of patients with uncontrolled persistent allergic asthma (AA) in the healthcare setting of the Czech Republic, from a global non-interventional, 2-year post-marketing, observational eXpeRience registry.
    Aim: To evaluate the real-life effectiveness and safety of omalizumab.
    Material and methods: Patients with uncontrolled persistent AA (currently defined by the Global Initiative for Asthma (GINA) as uncontrolled severe AA) who started omalizumab treatment 15 weeks before inclusion in the registry were analysed for physicians' global evaluation of treatment effectiveness (GETE), asthma symptoms, corticosteroid use, exacerbation rate, asthma control, quality of life, healthcare utilisation and safety during a 24-month observation period.
    Results: One hundred and fourteen patients from the Czech Republic were enrolled in the eXpeRience registry. A total of 88.9% of the patients were evaluated as responders to omalizumab according to the GETE assessment at week 16. From baseline to month 24: mean change in forced expiratory volume in 1 s (FEV
    Conclusions: The results of this subgroup analysis support the evidence that add-on omalizumab therapy is effective and well tolerated for management of patients with uncontrolled persistent AA in the Czech Republic. Global evaluation of treatment effectiveness assessment is a reliable predictor of long-term response to omalizumab treatment.
    Language English
    Publishing date 2018-06-20
    Publishing country Poland
    Document type Journal Article
    ZDB-ID 2596142-1
    ISSN 1642-395X
    ISSN 1642-395X
    DOI 10.5114/ada.2018.76606
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Serum periostin levels in asthma patients in relation to omalizumab therapy and presence of chronic rhinosinusitis with nasal polyps.

    Novosad, Jakub / Krčmová, Irena / Bartoš, Vladimír / Drahošová, Marcela / Vaník, Petr / Růžičková-Kirchnerová, Olga / Teřl, Milan / Krejsek, Jan

    Postepy dermatologii i alergologii

    2020  Volume 37, Issue 2, Page(s) 240–249

    Abstract: Introduction: The serum periostin level is a promising biomarker of type 2- high inflammation pattern of bronchial asthma. It has been proven that serum periostin levels decrease in response to systemic and inhaled corticosteroid (ICS) therapy. However, ...

    Abstract Introduction: The serum periostin level is a promising biomarker of type 2- high inflammation pattern of bronchial asthma. It has been proven that serum periostin levels decrease in response to systemic and inhaled corticosteroid (ICS) therapy. However, we have only limited knowledge about changes in serum periostin levels reflecting omalizumab (OMA) treatment and other variables, such as chronic rhinosinusitis with nasal polyps (CRSwNP).
    Aim: To critically appraise clinically relevant parameters influencing periostin levels in asthma patients.
    Material and methods: A pilot, cross-sectional, observational study to assess serum periostin levels of 48 asthma patients (38 treated by conventional therapy comprising ICS and 10 treated by ICS and OMA as an add-on therapy) with respect to asthma clinical traits, comorbidities and to other biomarkers of type 2-high asthma phenotype (total IgE, absolute and relative eosinophil count, eosinophilic cationic protein (ECP) and a fraction of exhaled NO (FeNO)).
    Results: Serum periostin correlates with total IgE levels (Spearman rho = 0.364,
    Conclusions: Serum periostin production is significantly associated with treatment modality (omalizumab vs. conventional) and presence of CRSwNP. These variables need to be taken into account to interpret periostin levels accurately.
    Language English
    Publishing date 2020-05-06
    Publishing country Poland
    Document type Journal Article
    ZDB-ID 2596142-1
    ISSN 1642-395X
    ISSN 1642-395X
    DOI 10.5114/ada.2020.94842
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top